Skip to content
  • Follow Us

CarboHyde

SUGAR IS LIFE

  • Home
  • About Us
  • Pipeline
  • Technology
  • Investors and Partnering
  • Career
  • CarboHyde News
  • CarboHyde’s Blog
  • Home
  • About Us
  • Pipeline
  • Technology
  • Investors and Partnering
  • Career
  • CarboHyde News
  • CarboHyde’s Blog

CarboHyde

SUGAR IS LIFE

  • Home
  • About Us
  • Pipeline
  • Technology
  • Investors and Partnering
  • Career
  • CarboHyde News
  • CarboHyde’s Blog

Palleon Pharmaceuticals announces issuance of a U.S. Patent for the use of antibody sialidase conjugates

Oct 26, 2022Tamas Sohajdacarbohydrates, drug development, drug discoverycancer research, cancer treatment, immunology, immunooncology

We are always thrilled to see companies adjancing drugs in the field of glycochemistry, just as Palleon Pharmaceuticals. who recently announced patenting engineered human sialidase enzymes that restore antitumor immunity by degrading immunosuppressive sialoglycans on tumors and across immune cell types

Press releases

Prev
Next
Developed by Shuttle Themes. Powered by WordPress.
  • Contact Us
  • LinkedIn
  • Twitter